India Glycols · NSE: INDIAGLYCO · BSE: 500201

Q4 FY25 results · Jan–Mar 2025

India Glycols reported revenue from operations of ₹2,188.65 crore (up 7.3% from Q4 FY24) and net profit of ₹64.02 crore (up 51.7% from Q4 FY24) for Q4 FY25 (Jan–Mar 2025), on a consolidated basis.

Consolidated · ₹ crore
ItemQ4 FY25Q4 FY24YoYQ3 FY25QoQ
Revenue from operations2,188.652,039.08+7.3%2,424.01−9.7%
Other income1.594.65−65.8%5.82−72.7%
Total income2,190.242,043.73+7.2%2,429.83−9.9%
Profit before share of associates & JVs and tax70.4150.56+39.3%57.94+21.5%
Share of profit/(loss) of associates & JVs11.385.0413.48
Net profit for the period64.0242.21+51.7%56.81+12.7%
EPS, basic (₹)20.6813.63+51.7%18.35+12.7%
Net margin (%)2.92.12.3

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
ItemQ4 FY25Q4 FY24YoYQ3 FY25QoQ
Revenue from operations2,188.002,036.57+7.4%2,423.76−9.7%
Other income1.594.65−65.8%5.82−72.7%
Total income2,189.592,041.22+7.3%2,429.58−9.9%
Profit before tax68.1251.13+33.2%58.45+16.5%
Net profit for the period50.3537.74+33.4%43.84+14.8%
EPS, basic (₹)16.2612.19+33.4%14.16+14.8%
Net margin (%)2.31.91.8
Consolidated
Filed with BSE
16 May 2025, 19:50 IST
Board meeting
16 May 2025
Period
01 Jan 2025 to 31 Mar 2025
Review status
Audited
Source
XBRL filing on BSE
Standalone
Filed with BSE
16 May 2025, 19:50 IST
Board meeting
16 May 2025
Period
01 Jan 2025 to 31 Mar 2025
Review status
Audited
Source
XBRL filing on BSE